Composite diffuse large B-cell and peripheral T-cell lymphoma with T-helper phenotype treated with both rituximab and brentuximab vedotin
Gespeichert in:
| Veröffentlicht in: | Annals of hematology 2021-11, Vol.100 (11), p.2873-2875 |
|---|---|
| Hauptverfasser: | , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 2875 |
|---|---|
| container_issue | 11 |
| container_start_page | 2873 |
| container_title | Annals of hematology |
| container_volume | 100 |
| creator | Ohya, Kouichi Okuyama, Shuhei Ogata, Shin-ya Maeda, Kunihiko Yamada, Kyohei Ohshima, Kouichi Tajima, Katsushi |
| description | |
| doi_str_mv | 10.1007/s00277-021-04633-6 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_journals_2581106857</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>2581106857</sourcerecordid><originalsourceid>FETCH-LOGICAL-c293t-b37bbaf2800e4b7c84e306cbbceb8c43a2ccb334b7194224525723ac91303b7b3</originalsourceid><addsrcrecordid>eNp9kM1O3TAQha2qqFxoX4AFstS16fgnf8v2ClokJDawtmxnwg1K4tR2Wu4j8NYYAmVXL2zNzHfOWIeQEw5nHKD6FgFEVTEQnIEqpWTlB7LhSgoGRa0-kg00smFFPofkKMZ7AC5qJT6RQ6lUVsp6Qx63fpx97BPStu-6JSIdTLhD-oM5HAZqppbOGPp5h8EM9GbtDvtx3vnR0L992uXmDocM0QxNPu1npCmgSdiuc-vzFfq0PPSjsS-WNuD0Vv_B1qd--kwOOjNE_PL6HpPbi_Ob7S92df3zcvv9ijnRyMSsrKw1nagBUNnK1QollM5ah7Z2ShrhnJUyj3ijhFCFKCohjWu4BGkrK4_J19V3Dv73gjHpe7-EKa_Uoqg5h7IuqkyJlXLBxxiw03PIvw17zUE_p6_X9HVOX7-kr8ssOn21XuyI7T_JW9wZkCsQ82i6w_C--z-2TzYrkf4</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2581106857</pqid></control><display><type>article</type><title>Composite diffuse large B-cell and peripheral T-cell lymphoma with T-helper phenotype treated with both rituximab and brentuximab vedotin</title><source>MEDLINE</source><source>SpringerLink (Online service)</source><creator>Ohya, Kouichi ; Okuyama, Shuhei ; Ogata, Shin-ya ; Maeda, Kunihiko ; Yamada, Kyohei ; Ohshima, Kouichi ; Tajima, Katsushi</creator><creatorcontrib>Ohya, Kouichi ; Okuyama, Shuhei ; Ogata, Shin-ya ; Maeda, Kunihiko ; Yamada, Kyohei ; Ohshima, Kouichi ; Tajima, Katsushi</creatorcontrib><identifier>ISSN: 0939-5555</identifier><identifier>EISSN: 1432-0584</identifier><identifier>DOI: 10.1007/s00277-021-04633-6</identifier><identifier>PMID: 34427738</identifier><language>eng</language><publisher>Berlin/Heidelberg: Springer Berlin Heidelberg</publisher><subject>Aged, 80 and over ; Antineoplastic Agents, Immunological - therapeutic use ; Antineoplastic Combined Chemotherapy Protocols - therapeutic use ; Brentuximab Vedotin - therapeutic use ; Female ; Hematology ; Humans ; Letter to the Editor ; Lymphoma, Large B-Cell, Diffuse - complications ; Lymphoma, Large B-Cell, Diffuse - drug therapy ; Lymphoma, T-Cell, Peripheral - complications ; Lymphoma, T-Cell, Peripheral - drug therapy ; Medicine ; Medicine & Public Health ; Oncology ; Rituximab - therapeutic use ; T-Lymphocytes, Helper-Inducer - drug effects</subject><ispartof>Annals of hematology, 2021-11, Vol.100 (11), p.2873-2875</ispartof><rights>The Author(s), under exclusive licence to Springer-Verlag GmbH Germany, part of Springer Nature 2021</rights><rights>The Author(s), under exclusive licence to Springer-Verlag GmbH Germany, part of Springer Nature 2021.</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><cites>FETCH-LOGICAL-c293t-b37bbaf2800e4b7c84e306cbbceb8c43a2ccb334b7194224525723ac91303b7b3</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://link.springer.com/content/pdf/10.1007/s00277-021-04633-6$$EPDF$$P50$$Gspringer$$H</linktopdf><linktohtml>$$Uhttps://link.springer.com/10.1007/s00277-021-04633-6$$EHTML$$P50$$Gspringer$$H</linktohtml><link.rule.ids>314,776,780,27903,27904,41467,42536,51297</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/34427738$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Ohya, Kouichi</creatorcontrib><creatorcontrib>Okuyama, Shuhei</creatorcontrib><creatorcontrib>Ogata, Shin-ya</creatorcontrib><creatorcontrib>Maeda, Kunihiko</creatorcontrib><creatorcontrib>Yamada, Kyohei</creatorcontrib><creatorcontrib>Ohshima, Kouichi</creatorcontrib><creatorcontrib>Tajima, Katsushi</creatorcontrib><title>Composite diffuse large B-cell and peripheral T-cell lymphoma with T-helper phenotype treated with both rituximab and brentuximab vedotin</title><title>Annals of hematology</title><addtitle>Ann Hematol</addtitle><addtitle>Ann Hematol</addtitle><subject>Aged, 80 and over</subject><subject>Antineoplastic Agents, Immunological - therapeutic use</subject><subject>Antineoplastic Combined Chemotherapy Protocols - therapeutic use</subject><subject>Brentuximab Vedotin - therapeutic use</subject><subject>Female</subject><subject>Hematology</subject><subject>Humans</subject><subject>Letter to the Editor</subject><subject>Lymphoma, Large B-Cell, Diffuse - complications</subject><subject>Lymphoma, Large B-Cell, Diffuse - drug therapy</subject><subject>Lymphoma, T-Cell, Peripheral - complications</subject><subject>Lymphoma, T-Cell, Peripheral - drug therapy</subject><subject>Medicine</subject><subject>Medicine & Public Health</subject><subject>Oncology</subject><subject>Rituximab - therapeutic use</subject><subject>T-Lymphocytes, Helper-Inducer - drug effects</subject><issn>0939-5555</issn><issn>1432-0584</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2021</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><sourceid>ABUWG</sourceid><sourceid>AFKRA</sourceid><sourceid>BENPR</sourceid><sourceid>CCPQU</sourceid><recordid>eNp9kM1O3TAQha2qqFxoX4AFstS16fgnf8v2ClokJDawtmxnwg1K4tR2Wu4j8NYYAmVXL2zNzHfOWIeQEw5nHKD6FgFEVTEQnIEqpWTlB7LhSgoGRa0-kg00smFFPofkKMZ7AC5qJT6RQ6lUVsp6Qx63fpx97BPStu-6JSIdTLhD-oM5HAZqppbOGPp5h8EM9GbtDvtx3vnR0L992uXmDocM0QxNPu1npCmgSdiuc-vzFfq0PPSjsS-WNuD0Vv_B1qd--kwOOjNE_PL6HpPbi_Ob7S92df3zcvv9ijnRyMSsrKw1nagBUNnK1QollM5ah7Z2ShrhnJUyj3ijhFCFKCohjWu4BGkrK4_J19V3Dv73gjHpe7-EKa_Uoqg5h7IuqkyJlXLBxxiw03PIvw17zUE_p6_X9HVOX7-kr8ssOn21XuyI7T_JW9wZkCsQ82i6w_C--z-2TzYrkf4</recordid><startdate>20211101</startdate><enddate>20211101</enddate><creator>Ohya, Kouichi</creator><creator>Okuyama, Shuhei</creator><creator>Ogata, Shin-ya</creator><creator>Maeda, Kunihiko</creator><creator>Yamada, Kyohei</creator><creator>Ohshima, Kouichi</creator><creator>Tajima, Katsushi</creator><general>Springer Berlin Heidelberg</general><general>Springer Nature B.V</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7RV</scope><scope>7X7</scope><scope>7XB</scope><scope>88E</scope><scope>8AO</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>BENPR</scope><scope>CCPQU</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>K9.</scope><scope>KB0</scope><scope>M0S</scope><scope>M1P</scope><scope>NAPCQ</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope></search><sort><creationdate>20211101</creationdate><title>Composite diffuse large B-cell and peripheral T-cell lymphoma with T-helper phenotype treated with both rituximab and brentuximab vedotin</title><author>Ohya, Kouichi ; Okuyama, Shuhei ; Ogata, Shin-ya ; Maeda, Kunihiko ; Yamada, Kyohei ; Ohshima, Kouichi ; Tajima, Katsushi</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c293t-b37bbaf2800e4b7c84e306cbbceb8c43a2ccb334b7194224525723ac91303b7b3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2021</creationdate><topic>Aged, 80 and over</topic><topic>Antineoplastic Agents, Immunological - therapeutic use</topic><topic>Antineoplastic Combined Chemotherapy Protocols - therapeutic use</topic><topic>Brentuximab Vedotin - therapeutic use</topic><topic>Female</topic><topic>Hematology</topic><topic>Humans</topic><topic>Letter to the Editor</topic><topic>Lymphoma, Large B-Cell, Diffuse - complications</topic><topic>Lymphoma, Large B-Cell, Diffuse - drug therapy</topic><topic>Lymphoma, T-Cell, Peripheral - complications</topic><topic>Lymphoma, T-Cell, Peripheral - drug therapy</topic><topic>Medicine</topic><topic>Medicine & Public Health</topic><topic>Oncology</topic><topic>Rituximab - therapeutic use</topic><topic>T-Lymphocytes, Helper-Inducer - drug effects</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Ohya, Kouichi</creatorcontrib><creatorcontrib>Okuyama, Shuhei</creatorcontrib><creatorcontrib>Ogata, Shin-ya</creatorcontrib><creatorcontrib>Maeda, Kunihiko</creatorcontrib><creatorcontrib>Yamada, Kyohei</creatorcontrib><creatorcontrib>Ohshima, Kouichi</creatorcontrib><creatorcontrib>Tajima, Katsushi</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>Nursing & Allied Health Source (ProQuest)</collection><collection>Health & Medical Complete (ProQuest Database)</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Medical Database (Alumni Edition)</collection><collection>ProQuest Pharma Collection</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>ProQuest Central (Alumni)</collection><collection>ProQuest Central UK/Ireland</collection><collection>ProQuest Central</collection><collection>ProQuest One Community College</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>Nursing & Allied Health Database (Alumni Edition)</collection><collection>Health & Medical Collection (Alumni Edition)</collection><collection>Medical Database</collection><collection>Nursing & Allied Health Premium</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><jtitle>Annals of hematology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Ohya, Kouichi</au><au>Okuyama, Shuhei</au><au>Ogata, Shin-ya</au><au>Maeda, Kunihiko</au><au>Yamada, Kyohei</au><au>Ohshima, Kouichi</au><au>Tajima, Katsushi</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Composite diffuse large B-cell and peripheral T-cell lymphoma with T-helper phenotype treated with both rituximab and brentuximab vedotin</atitle><jtitle>Annals of hematology</jtitle><stitle>Ann Hematol</stitle><addtitle>Ann Hematol</addtitle><date>2021-11-01</date><risdate>2021</risdate><volume>100</volume><issue>11</issue><spage>2873</spage><epage>2875</epage><pages>2873-2875</pages><issn>0939-5555</issn><eissn>1432-0584</eissn><cop>Berlin/Heidelberg</cop><pub>Springer Berlin Heidelberg</pub><pmid>34427738</pmid><doi>10.1007/s00277-021-04633-6</doi><tpages>3</tpages></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0939-5555 |
| ispartof | Annals of hematology, 2021-11, Vol.100 (11), p.2873-2875 |
| issn | 0939-5555 1432-0584 |
| language | eng |
| recordid | cdi_proquest_journals_2581106857 |
| source | MEDLINE; SpringerLink (Online service) |
| subjects | Aged, 80 and over Antineoplastic Agents, Immunological - therapeutic use Antineoplastic Combined Chemotherapy Protocols - therapeutic use Brentuximab Vedotin - therapeutic use Female Hematology Humans Letter to the Editor Lymphoma, Large B-Cell, Diffuse - complications Lymphoma, Large B-Cell, Diffuse - drug therapy Lymphoma, T-Cell, Peripheral - complications Lymphoma, T-Cell, Peripheral - drug therapy Medicine Medicine & Public Health Oncology Rituximab - therapeutic use T-Lymphocytes, Helper-Inducer - drug effects |
| title | Composite diffuse large B-cell and peripheral T-cell lymphoma with T-helper phenotype treated with both rituximab and brentuximab vedotin |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-24T16%3A43%3A12IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Composite%20diffuse%20large%20B-cell%20and%20peripheral%20T-cell%20lymphoma%20with%20T-helper%20phenotype%20treated%20with%20both%20rituximab%20and%20brentuximab%20vedotin&rft.jtitle=Annals%20of%20hematology&rft.au=Ohya,%20Kouichi&rft.date=2021-11-01&rft.volume=100&rft.issue=11&rft.spage=2873&rft.epage=2875&rft.pages=2873-2875&rft.issn=0939-5555&rft.eissn=1432-0584&rft_id=info:doi/10.1007/s00277-021-04633-6&rft_dat=%3Cproquest_cross%3E2581106857%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2581106857&rft_id=info:pmid/34427738&rfr_iscdi=true |